GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Beneish M-Score

OmniAb (OmniAb) Beneish M-Score : 1.74 (As of Jun. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.74 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for OmniAb's Beneish M-Score or its related term are showing as below:

OABI' s Beneish M-Score Range Over the Past 10 Years
Min: -4.45   Med: -2.82   Max: 1.74
Current: 1.74

During the past 5 years, the highest Beneish M-Score of OmniAb was 1.74. The lowest was -4.45. And the median was -2.82.


OmniAb Beneish M-Score Historical Data

The historical data trend for OmniAb's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Beneish M-Score Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - -2.39 -4.45

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.82 -3.14 -4.45 1.74

Competitive Comparison of OmniAb's Beneish M-Score

For the Biotechnology subindustry, OmniAb's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OmniAb's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where OmniAb's Beneish M-Score falls into.



OmniAb Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of OmniAb for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 7.013+0.528 * 1+0.404 * 1.1103+0.892 * 0.3171+0.115 * 0.92
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.6399+4.679 * -0.059871-0.327 * 1.0116
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $4.05 Mil.
Revenue was 3.801 + 4.822 + 5.477 + 6.946 = $21.05 Mil.
Gross Profit was 3.801 + 4.822 + 5.477 + 6.946 = $21.05 Mil.
Total Current Assets was $76.72 Mil.
Total Assets was $352.56 Mil.
Property, Plant and Equipment(Net PPE) was $37.32 Mil.
Depreciation, Depletion and Amortization(DDA) was $19.59 Mil.
Selling, General, & Admin. Expense(SGA) was $33.46 Mil.
Total Current Liabilities was $17.52 Mil.
Long-Term Debt & Capital Lease Obligation was $21.42 Mil.
Net Income was -18.961 + -14.053 + -15.738 + -14.728 = $-63.48 Mil.
Non Operating Income was 0 + -0.003 + 0.008 + -0.004 = $0.00 Mil.
Cash Flow from Operations was -17.032 + -9.121 + -6.198 + -10.022 = $-42.37 Mil.
Total Receivables was $1.82 Mil.
Revenue was 16.919 + 35.345 + 6.91 + 7.199 = $66.37 Mil.
Gross Profit was 16.919 + 35.345 + 6.91 + 7.199 = $66.37 Mil.
Total Current Assets was $121.08 Mil.
Total Assets was $413.04 Mil.
Property, Plant and Equipment(Net PPE) was $40.29 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.67 Mil.
Selling, General, & Admin. Expense(SGA) was $28.99 Mil.
Total Current Liabilities was $21.68 Mil.
Long-Term Debt & Capital Lease Obligation was $23.42 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.045 / 21.046) / (1.819 / 66.373)
=0.192198 / 0.027406
=7.013

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(66.373 / 66.373) / (21.046 / 21.046)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (76.717 + 37.319) / 352.556) / (1 - (121.081 + 40.286) / 413.041)
=0.676545 / 0.60932
=1.1103

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.046 / 66.373
=0.3171

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.67 / (18.67 + 40.286)) / (19.587 / (19.587 + 37.319))
=0.316677 / 0.344199
=0.92

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(33.455 / 21.046) / (28.986 / 66.373)
=1.589613 / 0.436714
=3.6399

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((21.418 + 17.52) / 352.556) / ((23.418 + 21.677) / 413.041)
=0.110445 / 0.109178
=1.0116

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-63.48 - 0.001 - -42.373) / 352.556
=-0.059871

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

OmniAb has a M-score of 1.74 signals that the company is likely to be a manipulator.


OmniAb (OmniAb) Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010